NCT03509636View on ClinicalTrials.gov

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

August 26, 2019

Study Completion Date

July 23, 2020

Conditions
Ovarian Cancer
Interventions
DRUG

Fluzoparib

Fluzoparib capsule will be given twice daily orally

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03509636 - A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | Biotech Hunter | Biotech Hunter